Margaret McLoughlin
CIK 1770823 · last filed 2026-01-21
Margaret McLoughlin is a corporate insider who has filed 14 SEC Form 4 insider transactions across 2 companies since 2019. The most recent filing, for QNCX, was dated Jan 21, 2026. Across all open-market trades the lifetime net is −$672.7K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $7.5K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$7.5K
2
14
-$672.7K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| QNCX | Director | 8,000 | $0.93 | $7.5K | $9.8K | 6 | 2026-01-21 |
| Quince Therapeutics, Inc. (CRTX) Delisted | Director | 1,000 | $1.95 | $1.9K | -$682.6K | 8 | 2022-06-09 |
Recent Filings
14 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-01-21 | QNCX | Grant (A) | — | $0 | EDGAR |
| 2025-06-06 | QNCX | Grant (A) | — | $0 | EDGAR |
| 2025-01-08 | QNCX | Grant (A) | — | $0 | EDGAR |
| 2024-06-07 | QNCX | Grant (A) | — | $0 | EDGAR |
| 2023-08-09 | QNCX | Buy (P) | +8,000 | $9.8K | EDGAR |
| 2023-05-26 | QNCX | Grant (A) | — | $0 | EDGAR |
| 2022-06-09 | Quince Therapeutics, Inc. (CRTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-10-12 | Quince Therapeutics, Inc. (CRTX) Delisted | Mixed | — | -$71.9K | EDGAR |
| 2021-08-18 | Quince Therapeutics, Inc. (CRTX) Delisted | Mixed | — | -$470.6K | EDGAR |
| 2021-06-29 | Quince Therapeutics, Inc. (CRTX) Delisted | Sell (S) | −550 | -$30.3K | EDGAR |